Technology | Antiplatelet and Anticoagulation Therapies | October 17, 2018

FDA Clears Rivaroxaban to Reduce the Risk of Major Cardiovascular Events

New indication is for patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD)

Rivaroxaban (Xeralto) is now cleared by the FDA with a new indication is for patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).

October 17, 2018 — The U.S. Food and Drug Administration (FDA) has cleared an additional indication for rivaroxaban (Xarelto) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction (MI) and stroke, in people with chronic coronary or peripheral artery disease (CAD/PAD). The drug is now the first and only factor Xa inhibitor approved for patients living with these conditions. The drug is made by The Janssen Pharmaceutical Companies of Johnson and Johnson. 

This new indication is based on results from the landmark COMPASS Trial,[1] which showed a significant 24 percent reduction of the risk of major CV events in patients with chronic CAD and/or PAD with the rivaroxaban vascular dose of 2.5 mg twice daily plus aspirin 100 mg once daily, compared to aspirin alone. This finding was driven by a 42 percent reduction in stroke, 22 percent reduction in CV death and 14 percent reduction in heart attack. The risk of major bleeding was significantly higher in patients taking the rivaroxaban/aspirin regimen compared to aspirin alone, with no significant increase in fatal or intracranial bleeds.

“Treating patients with aspirin only is simply not enough to address the underlying thrombotic risk that comes with CAD and PAD,” said Kelley Branch, M.D., M.Sc., FACC, FSCCT, associate professor in cardiology, University of Washington, Seattle. “As we saw in the COMPASS Trial, the dual pathway approach of aspirin and the 2.5 mg, twice-daily dose of Xarelto can help significantly reduce the risk of CV events in these populations.”

Both chronic CAD and PAD occur when arteries become hardened or narrowed due to a buildup of cholesterol and plaque, potentially limiting blood flow to parts of the body. Known as atherosclerosis, this disease is rarely fatal, but is the most frequent underlying cause of CAD and PAD, which affect 16.5 million and 10 million Americans, 13 million of whom are currently diagnosed. When left untreated, atherosclerosis can lead to serious problems, including heart attack, stroke and death.[2,3]

“Despite the use of guideline-recommended therapies, patients with chronic CAD and/or PAD remain at risk of having a devastating and irreversible CV event,” said Paul Burton, M.D., Ph.D., FACC, vice president, medical affairs, internal medicine, Janssen Scientific Affairs LLC. “The new Xarelto vascular 2.5 mg dose, when used with aspirin, represents a true breakthrough for patients with chronic CAD and PAD.”

Details on the COMPASS Trial

COMPASS was a phase 3 clinical study of 27,395 patients with chronic CAD or PAD from 33 countries, examined the use of rivaroxaban, alone or in combination with aspirin, for the long-term prevention of major adverse CV events, including heart attack, stroke and CV death. In February 2017, COMPASS was stopped early for efficacy based on recommendation of the Independent Data and Safety Monitoring Board who observed a consistent difference in the primary outcome in favor of rivaroxaban 2.5 mg plus aspirin. The COMPASS results were presented during a Hot Line session at the ESC Congress 2017 and simultaneously published in The New England Journal of Medicine.[1] Two sub-analyses from COMPASS in patients with PAD and CAD were also published in The Lancet

COMPASS is a part of the industry-leading EXPLORER clinical development program, a collaborative effort between Janssen and Bayer, which seeks to generate important clinical evidence on the safety and efficacy of rivaroxaban and its potential role in addressing a wide range of critical medical needs. 

Read about the results of rivaroxaban in PAD from the late-breakers at ACC 2018. 

In July 2018, Janssen’s development partner Bayer announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion to update the rivaroxaban label to include the new vascular indication in the European Union; the European Commission granted approval on Aug. 24, 2018. Since its launch, rivaroxaban has been approved for a variety of indications and prescribed more than 45 million times worldwide.

 

References:

1. J.W. Eikelboom, S.J. Connolly, J. Bosch, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319-30. DOI: 10.1056/NEJMoa1709118

2. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation. 2017; CIR.0000000000000485;ii AHA Statistical Update. Originally published Jan. 25, 2017, page 360.

3. AHA Statistical Update, Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation. 2017;CIR.0000000000000485. Originally published Jan. 25, 2017, page 408. h

Related Content

Experimental Vaccine May Reduce Post-Stroke Blood Clot Risk
News | Antiplatelet and Anticoagulation Therapies | November 01, 2018
A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes caused by blood...
Thrombolytic Science Initiates Phase 2 Trial of Novel Ischemic Stroke Treatment Regimen
News | Antiplatelet and Anticoagulation Therapies | September 07, 2018
A new Phase 2 clinical trial looks to confirm the efficacy and safety of Thrombolytic Science LLC’s (TSI) sequential...
Bleeds and Benefit With Aspirin Balanced in Diabetes Patients
News | Antiplatelet and Anticoagulation Therapies | September 05, 2018
Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease,...
Extended Post-Hospital Oral Anticoagulant Use Reduces Non-Fatal Blood Clots
News | Antiplatelet and Anticoagulation Therapies | August 31, 2018
Use of an oral anticoagulant in medically ill patients for 45 days following hospital discharge reduces the rate of non...
AFib Patients Want More Information About Anticoagulation Reversal
News | Antiplatelet and Anticoagulation Therapies | June 27, 2018
Results from a 902-person, five-country survey of people living with atrial fibrillation (AF) reinforce the importance...
Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin. #HRS 2018
News | Antiplatelet and Anticoagulation Therapies | May 18, 2018
May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

 

Feature | Antiplatelet and Anticoagulation Therapies | May 07, 2018
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated...
The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association. #ACC18

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association.

News | Antiplatelet and Anticoagulation Therapies | March 19, 2018
The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in...
The Xarelto booth at ACC.18

The Xarelto booth at the 2018 American College of Cardiology meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 14, 2018
March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiolo
Xarelto Reduces Ischemic Stroke for Coronary and Peripheral Artery Disease Patients
News | Antiplatelet and Anticoagulation Therapies | February 19, 2018
A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International Stroke Conference (ISC...
Overlay Init